FR07C0012I1 - - Google Patents

Info

Publication number
FR07C0012I1
FR07C0012I1 FR07C0012C FR07C0012I1 FR 07C0012 I1 FR07C0012 I1 FR 07C0012I1 FR 07C0012 C FR07C0012 C FR 07C0012C FR 07C0012 I1 FR07C0012 I1 FR 07C0012I1
Authority
FR
France
Prior art keywords
vlps
particles
papillomavirus
disassembled
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR07C0012I1 publication Critical patent/FR07C0012I1/fr
Application granted granted Critical
Publication of FR07C0012I2 publication Critical patent/FR07C0012I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR07C0012C 1997-09-05 2007-02-21 Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus Active FR07C0012I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92399797A 1997-09-05 1997-09-05
PCT/US1998/016464 WO1999013056A1 (en) 1997-09-05 1998-08-19 IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)

Publications (2)

Publication Number Publication Date
FR07C0012I1 true FR07C0012I1 (es) 2007-03-30
FR07C0012I2 FR07C0012I2 (fr) 2007-10-26

Family

ID=25449564

Family Applications (1)

Application Number Title Priority Date Filing Date
FR07C0012C Active FR07C0012I2 (fr) 1997-09-05 2007-02-21 Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus

Country Status (16)

Country Link
US (2) US6261765B1 (es)
EP (2) EP1015561B1 (es)
JP (2) JP4199416B2 (es)
AT (1) ATE333501T1 (es)
AU (1) AU742409B2 (es)
CA (1) CA2302545C (es)
CY (2) CY1107987T1 (es)
DE (3) DE122007000015I2 (es)
DK (1) DK1015561T3 (es)
ES (2) ES2572628T3 (es)
FR (1) FR07C0012I2 (es)
HK (1) HK1030797A1 (es)
LU (1) LU91314I2 (es)
NL (1) NL300264I2 (es)
PT (1) PT1015561E (es)
WO (1) WO1999013056A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
AU732125B2 (en) * 1996-07-17 2001-04-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious papillomavirus pseudoviral particles
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
ATE426803T1 (de) 1999-12-09 2009-04-15 Medimmune Inc In-vitro-methode zur zerlegung und zum wiederzusammenfugen von papillomavirusartigen partikeln
DE60137230D1 (de) * 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
AU2001294565A1 (en) * 2000-09-18 2002-04-02 Med Immune, Inc. In vitro assay for measuring the immunogenicity of a vaccine
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10224111A1 (de) * 2002-05-29 2003-12-18 November Ag Molekulare Medizin Verfahren zum Assemblieren von Untereinheiten zu Kapsoiden
AU2003237528A1 (en) * 2002-06-07 2003-12-22 Kentucky Bioprocessing, Llc Flexible vaccine assembly and vaccine delivery platform
EA200701633A1 (ru) 2002-12-20 2007-12-28 Глаксосмитклайн Байолоджикалс С.А. Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
EP1785433A4 (en) 2004-07-01 2008-10-01 Tokyo Inst Tech VIRUS PARTICULAR CONSTRUCT AND METHOD FOR THEIR EDUCATION UNDER PHYSIOLOGICAL CONDITIONS
BRPI0611336A2 (pt) * 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5284290B2 (ja) 2007-03-14 2013-09-11 リゴサイト ファーマスーティカルズ，インコーポレイテッド ウイルス様粒子の精製
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
EP2145189B1 (en) 2007-05-08 2016-04-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus pseudoviruses for detection and therapy of tumors
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
EA022213B1 (ru) 2009-06-25 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
EP2449096A4 (en) * 2009-07-03 2014-01-08 Univ Queensland PROCESS FOR PREPARING A PARTICULATE BIOLOGICAL STRUCTURE
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130115247A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CA2924684C (en) 2013-09-18 2021-02-09 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
AU2015313756A1 (en) * 2014-09-11 2017-03-09 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
RU2677336C2 (ru) * 2014-12-26 2019-01-16 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
AU2016343809B2 (en) 2015-10-30 2022-08-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
KR20180083868A (ko) 2015-10-30 2018-07-23 알레타 바이오쎄라퓨틱스, 인크. 종양 형질도입용 조성물 및 방법
GB201708709D0 (en) * 2017-06-01 2017-07-19 Univ York Virus like particle
KR20200084883A (ko) 2017-11-06 2020-07-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 기존의 미생물 면역을 활용한 암 치료
JP2021502822A (ja) 2017-11-14 2021-02-04 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス
GB202011609D0 (en) 2020-07-27 2020-09-09 Univ Leeds Innovations Ltd Coronaviral packaging signals
WO2024111566A1 (ja) * 2022-11-22 2024-05-30 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016638A1 (en) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique

Also Published As

Publication number Publication date
US6261765B1 (en) 2001-07-17
JP2001515922A (ja) 2001-09-25
WO1999013056A1 (en) 1999-03-18
DE69835294T2 (de) 2007-07-26
DE69835294D1 (de) 2006-08-31
CY1107987T1 (el) 2011-04-06
CA2302545A1 (en) 1999-03-18
JP4199416B2 (ja) 2008-12-17
FR07C0012I2 (fr) 2007-10-26
DE122007000015I2 (de) 2008-01-24
AU9015498A (en) 1999-03-29
ATE333501T1 (de) 2006-08-15
AU742409B2 (en) 2002-01-03
EP1700911A1 (en) 2006-09-13
DE122007000015I1 (de) 2007-05-24
HK1030797A1 (en) 2001-05-18
US6416945B1 (en) 2002-07-09
EP1700911B1 (en) 2016-04-06
LU91314I2 (fr) 2007-04-23
EP1015561A1 (en) 2000-07-05
CY2007007I2 (el) 2016-10-05
ES2572628T3 (es) 2016-06-01
ES2268787T3 (es) 2007-03-16
EP1015561B1 (en) 2006-07-19
PT1015561E (pt) 2006-11-30
NL300264I2 (nl) 2008-06-02
DK1015561T3 (da) 2006-11-13
JP2009057377A (ja) 2009-03-19
JP4486142B2 (ja) 2010-06-23
CA2302545C (en) 2012-04-03
NL300264I1 (nl) 2007-05-01
LU91314I9 (es) 2019-01-30
CY2007007I1 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
LU91314I9 (es)
NZ509610A (en) Process for purifying human papillomavirus virus-like particles using hydroxyapatite
PL317234A1 (en) Vaccines against papilloma virus
EP1394259A3 (en) Recombinant infectious non-segmented negative strand RNA virus
FR11C0022I1 (es)
AU8673391A (en) Catalyst composition for purification of exhaust gas, catalyst for purification of exhaust gas, and process for producing said catalyst
KR100905760B1 (ko) 클론된 뉴클레오타이드 서열로부터 감염성 호흡기세포 융합 바이러스의 생산방법
AU5998400A (en) In vitro reconstitution of segmented negative-strand rna viruses
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
AU5873696A (en) Method of preparing 3-haloalkyl-1h-pyrazoles
AU2127395A (en) Highly efficient production and isolation of viral particles
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
AU5265296A (en) Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
HK1045149A1 (en) Process to separate 1,3-propanediol or glycerol, or a mixture thereof from a biological mixture.
AU2001237347A1 (en) Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
WO1996029413A3 (en) Dna encoding human papilloma virus type 18
CA2333192A1 (en) Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-2h-pyran-2-one
AU1681095A (en) Hydrophilic signal oligopeptides and methods of therapeutic use
AU2002213901A1 (en) Method for regenerating a zeolite catalyst
AUPM358894A0 (en) Modified papilloma virus l2 protein and vlps formed therefrom
AU2001245737A1 (en) Method of recovering 1,3-propanediol from fermentation broth
EP0955367A3 (en) Recombinant nucleoprotein of toscana virus
AU2003235191A1 (en) Papilloma virus-like particles, fusion proteins as well as processes for their production